Fulgent Genetics, Inc. (FRA:7F0)
Germany · Delayed Price · Currency is EUR | Market Cap | 520.42M -8.5% |
| Revenue (ttm) | 283.54M +6.8% |
| Net Income | -73.86M |
| EPS | -2.46 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 18.90 |
| Previous Close | 18.70 |
| Day's Range | 18.90 - 18.90 |
| 52-Week Range | 11.80 - 26.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Fulgent Genetics
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he... [Read more]
Financial Performance
In 2025, Fulgent Genetics's revenue was $322.67 million, an increase of 13.83% compared to the previous year's $283.47 million. Losses were -$60.51 million, 41.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Fulgent Genetics Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 4% year-over-year to $85.4 million, driven by acquisitions, but billing system transition reduced collection rates and margins. Full-year revenue guidance was lowered to $330–$340 million, with continued investment in R&D and digital pathology.
Fulgent Genetics Earnings release: Q2 2026
Fulgent Genetics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Fulgent Genetics Slides: Q2 2026
Fulgent Genetics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Fulgent Genetics Quarterly report: Q2 2026
Fulgent Genetics has published its Q2 2026 quarterly earnings report on July 30, 2026.
Fulgent Reports Second Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Presents Updated FID-007 Data at ASCO 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development busin...
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Com...
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent...
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Fulgent Genetics Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined due to a major customer transition, but acquisitions and new product launches are expected to drive growth. Guidance for 2026 is reaffirmed, with improved margins and reduced customer concentration risk anticipated.
Fulgent Genetics Earnings release: Q1 2026
Fulgent Genetics released its Q1 2026 earnings on May 1, 2026, summarizing the period's financial results.
Fulgent Genetics Slides: Q1 2026
Fulgent Genetics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 1, 2026.
Fulgent Genetics Quarterly report: Q1 2026
Fulgent Genetics has published its Q1 2026 quarterly earnings report on May 1, 2026.
Fulgent Reports First Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics Proxy statement: Proxy filing
Fulgent Genetics filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Fulgent Genetics Proxy statement: Proxy filing
Fulgent Genetics filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development busi...
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fulgent Genetics, Inc. (“Fulgent" or the "Company") (NASDAQ:FLGT) investors that the firm has initiated an investigation in...
Fulgent Genetics Earnings Call Transcript: Q4 2025
Revenue grew 14% in 2025 to $322.7 million, driven by innovation in AI and digital pathology, but 2026 will see a major customer loss offset by acquisitions and new product launches. Gross margins will dip early in 2026 but are expected to recover as integration and organic growth accelerate.
Fulgent Genetics Annual report: Q4 2025
Fulgent Genetics has published its Q4 2025 annual report on February 27, 2026.
Fulgent Genetics Earnings release: Q4 2025
Fulgent Genetics released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.